Unsal Ebru, Atalay Figen, Atikcan Sükran, Yilmaz Aydin
Atatrk Chest Diseases and Thoracic Surgery Center, Ankara, Turkey.
Respir Med. 2004 Feb;98(2):93-8. doi: 10.1016/j.rmed.2003.07.001.
There is a subclinical activation of coagulation and fibrinolysis system in lung cancer. Alterations in hemostatic system are seen frequently in lung cancer correlated with the prognosis of disease. In this prospective study, our purpose was to investigate the prognostic significance of hemostatic markers in patients with lung cancer. The study comprised 58 patients (22 squamous cell carcinoma, 16 adenocarcinoma, 20 small cell carcinoma). There were 55 men (95%)and 3 women (5%) with a mean age of 61 years range (36-74). Plasma level of platelets (PLT), prothrombin time (PT), active partial thromboplastin time (aPTT), antithrombin III (AT III), fibrinogen (F) and D-dimer level were measured before the initiation of any therapy. Patients were followed up for 17 (12-20) months. The median survival was determined as 6.4 months. Three histopathologic groups; squamous cell carcinoma, adenocarcinoma and small cell carcinoma were compared for the hemostatic parameters. There were no statistically significant differences among the histopathologic types for any of the parameters (P > 0.05). Patients were divided into two groups as patients without distant metastasis (stages I,II,III) and with distant metastasis (stage IV). The group with distant metastasis had higher level of D-dimer than the other group (P < 0.05). However, there were no statistically significant differences for D-dimer level between stages IIIB and IV (P > 0.05). Patients having high D-dimer and low AT III level had poor survival in our study. Thus, high level of D-dimer and low AT III level were determined as correlated with short survival (P < 0.05). These results suggest that elevated plasma level of D-dimer and low AT III level might be a sign of poor prognosis in patients with lung cancer.
肺癌患者存在凝血和纤溶系统的亚临床激活。止血系统的改变在肺癌中很常见,且与疾病预后相关。在这项前瞻性研究中,我们的目的是探讨止血标志物对肺癌患者的预后意义。该研究纳入了58例患者(22例鳞状细胞癌、16例腺癌、20例小细胞癌)。其中男性55例(95%),女性3例(5%),平均年龄61岁(范围36 - 74岁)。在开始任何治疗前,检测血浆血小板(PLT)水平、凝血酶原时间(PT)、活化部分凝血活酶时间(aPTT)、抗凝血酶III(AT III)、纤维蛋白原(F)和D - 二聚体水平。对患者进行了17(12 - 20)个月的随访。中位生存期确定为6.4个月。比较了鳞状细胞癌、腺癌和小细胞癌这三个组织病理学组的止血参数。任何参数在组织病理学类型之间均无统计学显著差异(P > 0.05)。患者被分为无远处转移(I、II、III期)和有远处转移(IV期)两组。有远处转移的组D - 二聚体水平高于另一组(P < 0.05)。然而,IIIB期和IV期之间D - 二聚体水平无统计学显著差异(P > 0.05)。在我们的研究中,D - 二聚体水平高且AT III水平低的患者生存期较差。因此,确定D - 二聚体水平高和AT III水平低与生存期短相关(P < 0.05)。这些结果表明,血浆D - 二聚体水平升高和AT III水平降低可能是肺癌患者预后不良的一个标志。